Neurimmune and AICURA Announce Strategic Collaboration to Leverage AI for the Development of Alzheimer’s Disease Therapeutics

Collaboration aims to accelerate clinical research and improve patient outcomes using advanced AI capabilities

Neurimmune and AICURA Medical GmbH today announced a strategic collaboration to harness the latest breakthroughs in artificial intelligence (AI) for the development of therapeutics for the treatment of Alzheimer’s disease. The partnership will leverage advanced AI systems to design clinical programs with the goal of improving patient outcomes and accelerating drug development timelines.

As part of the collaboration, AICURA and Neurimmune will develop and validate algorithms designed to predict disease status, responses to treatment and potential safety risks. These developments will be based on AICURA’s AI capabilities and Neurimmune’s expertise in neurodegenerative diseases.

“Artificial intelligence can generate valuable insights to help develop targeted therapeutic solutions and guide clinical development of the next generation of treatments for patients with Alzheimer’s disease,” said Roger M. Nitsch, CEO & President of the Board of Neurimmune.

“Neurimmune is pioneering research & clinical development in neurodegenerative disease with an advancing pipeline of drug candidates and significant, multimodal data sets based on years of clinical research,” said Daniel Lichterfeld, CEO and Founder of AICURA Medical GmbH. “We look forward to collaborating with Neurimmune to unlock the full potential of its data to accelerate innovation and improve outcomes in Alzheimer’s disease.”

Based on results of the collaboration’s initial research phase, Neurimmune and AICURA have the option to extend the collaboration to develop, optimize, and commercialize software intended to be used for medical purposes (SaMDs) and drug development tools (DDTs) for neurodegenerative diseases to drive further innovations in the field of precision medicine.